The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity of abiraterone acetate in metastatic patients with castration-resistant prostate cancer (mCRPC) previously treated with ketoconazole: A prospective phase II study from the prostate cancer clinical trials consortium.
Won Kim
No relevant relationships to disclose
John Wilton
No relevant relationships to disclose
Li Zhang
No relevant relationships to disclose
Amy M. Lin
No relevant relationships to disclose
Lawrence Fong
No relevant relationships to disclose
Terence W. Friedlander
No relevant relationships to disclose
Andrew Caleb Hsieh
No relevant relationships to disclose
Rahul Raj Aggarwal
No relevant relationships to disclose
Tammy J. Rodvelt
No relevant relationships to disclose
Allison Morse
No relevant relationships to disclose
Jeffrey Bozeman
No relevant relationships to disclose
Vivian K. Weinberg
No relevant relationships to disclose
Arturo Molina
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
James Mohler
No relevant relationships to disclose
Gerald J. Fetterly
No relevant relationships to disclose
Russell Zelig Szmulewitz
No relevant relationships to disclose
Eric Jay Small
No relevant relationships to disclose
Charles J. Ryan
Honoraria - Janssen